Suchergebnisse - "Motoi, Noriko"

PubPharm (5)

1

STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-γ-induced Apoptosis in Urothelial Cancer

enthalten in: Anticancer research | 2024

von Fuchizawa, H. | Ando, K. | Motoi, N. | +10

2

Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC

enthalten in: Clinical lung cancer | 2021

von Takeyasu, Y. | Yoshida, T. | Shibaki, R. | +7

3

Clinical outcomes of pembrolizumab therapy in advanced-NSCLC patients with poor performance status (≥3) and high PD-L1 expression (TPS ≥50%) : A case series

enthalten in: Thoracic cancer | 2020

von Inaba-Higashiyama, R. | Yoshida, T. | Jo, H. | +3

4

Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer

enthalten in: Thoracic cancer | 2019

von Shibaki, R. | Murakami, S. | Shinno, Y. | +8

5

Programmed Death-Ligand 1 Immunohistochemistry Testing : A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2017

von Büttner, R. | Gosney, J. | Skov, B. | +11

CommentIn: J Thorac Dis. 2018 Mar;10 (3):1217-1219. - PMID 29708172

1
[1]